| Entry |
|
|---|
| Name |
Dexlansoprazole (INN/USAN);
Dexilant (TN) |
|---|
| Product |
|
|---|
| Generic |
|
|---|
| Formula |
C16H14F3N3O2S
|
|---|
| Exact mass |
369.0759
|
|---|
| Mol weight |
369.3615
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Gastrointestinal agent
DG01975 Agents for peptic ulcer
DG01646 Proton pump inhibitor (PPI)
Metabolizing enzyme substrate
DG01639 CYP2C19 substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
Metabolizing enzyme inhibitor
DG01933 CYP2C19 inhibitor
|
|---|
| Remark |
| Product (DG03298): | D08903<US> D12816<US> |
|
|---|
| Efficacy |
Anti-ulcerative, Proton pump inhibitor |
|---|
| Disease |
Gastroesophageal reflux disease [DS: H01602] |
|---|
| Comment |
Benzimidazole derivative
|
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Metabolism |
Enzyme: CYP2C19 [HSA: 1557], CYP3A4 [HSA: 1576]
|
|---|
| Interaction |
CYP inhibition: CYP2C19 [HSA: 1557]
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
A ALIMENTARY TRACT AND METABOLISM
A02 DRUGS FOR ACID RELATED DISORDERS
A02B DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
A02BC Proton pump inhibitors
A02BC06 Dexlansoprazole
D08903 Dexlansoprazole (INN/USAN) <US>
USP drug classification [BR:br08302]
Gastrointestinal Agents
Proton Pump Inhibitors
Dexlansoprazole
D08903 Dexlansoprazole (INN/USAN)
Drug groups [BR:br08330]
Gastrointestinal agent
DG01975 Agents for peptic ulcer
DG01646 Proton pump inhibitor (PPI)
DG03298 Dexlansoprazole
D08903 Dexlansoprazole
Metabolizing enzyme substrate
DG01639 CYP2C19 substrate
DG03298 Dexlansoprazole
D08903 Dexlansoprazole
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG03298 Dexlansoprazole
D08903 Dexlansoprazole
Metabolizing enzyme inhibitor
DG01933 CYP2C19 inhibitor
DG03298 Dexlansoprazole
D08903 Dexlansoprazole
Drug classes [BR:br08332]
Gastrointestinal agent
DG01646 Proton pump inhibitor (PPI)
D08903 Dexlansoprazole
Target-based classification of drugs [BR:br08310]
Enzymes
Hydrolases (EC3)
ATPase
ATP4
D08903 Dexlansoprazole (INN/USAN) <US>
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D08903
Pharmacogenomic biomarkers [br08341.html]
Polymorphisms and mutations affecting drug response
D08903
Drug groups [BR:br08330]
Gastrointestinal agent
DG01975 Agents for peptic ulcer
DG01646 Proton pump inhibitor (PPI)
DG03298 Dexlansoprazole
Metabolizing enzyme substrate
DG01639 CYP2C19 substrate
DG03298 Dexlansoprazole
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG03298 Dexlansoprazole
Metabolizing enzyme inhibitor
DG01933 CYP2C19 inhibitor
DG03298 Dexlansoprazole
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 25
1 C8x C 8.1200 -19.9500
2 C8x C 8.1200 -21.3500
3 C8x C 9.3324 -22.0500
4 C8y C 10.5449 -21.3500
5 C8y C 10.5449 -19.9500
6 C8x C 9.3324 -19.2500
7 N5x N 11.8764 -21.7826
8 C8y C 12.6993 -20.6500
9 N4x N 11.8764 -19.5174
10 S4a S 14.0700 -20.6500
11 C1b C 14.7700 -21.8624
12 O3c O 14.7700 -19.4376
13 C8y C 16.1698 -21.8624
14 C8y C 16.8603 -23.0580
15 C8y C 18.2603 -23.0578
16 C8x C 18.9601 -21.8453
17 C8x C 18.2697 -20.6498
18 N5x N 16.8697 -20.6499
19 C1a C 16.1749 -24.2452
20 O2a O 18.9510 -24.2532
21 C1b C 20.3696 -24.2532
22 C1d C 21.0556 -25.4406
23 X F 21.7556 -26.6531
24 X F 22.2680 -24.7406
25 X F 19.8432 -26.1406
BOND 27
1 1 2 2
2 2 3 1
3 3 4 2
4 4 5 1
5 5 6 2
6 1 6 1
7 4 7 1
8 7 8 2
9 8 9 1
10 5 9 1
11 8 10 1
12 10 11 1 #Down
13 10 12 2
14 11 13 1
15 13 14 2
16 14 15 1
17 15 16 2
18 16 17 1
19 17 18 2
20 13 18 1
21 14 19 1
22 15 20 1
23 20 21 1
24 21 22 1
25 22 23 1
26 22 24 1
27 22 25 1
|
|---|
